ClinicalTrials.gg
Status unknownNCT04364516CardioCHUVI-AFUpdated Apr 28, 2020

Retrospective Observational Registry of Patients With Atrial Fibrillation From Vigo´s Health Area

An observational study in Atrial Fibrillation, sponsored by Hospital Álvaro Cunqueiro. Status unknown at 1 site in Spain. Per ClinicalTrials.gov, last updated 2020-04-28.

Sponsored by Hospital Álvaro Cunqueiro · Observational

How we know

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
15,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 247 studies in Atrial Fibrillation with a site in Spain — 53 open to participants now, 76 under way, 3 of them phase 3. Atrial Fibrillation · Spain.

Planned enrollment
4th of 85
15,000 · median 500
Started
2018
with 11 others
Observational
85 of 247
15 open now
Registered
149th of 247
by date

Among the 247 studies in Atrial Fibrillation with a site in Spain, this one is the 4th largest by planned enrollment of the 85 observational ones that give a count, is one of 12 that started in 2018, is one of 85 observational ones, and was the 149th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

53 of the 247 studies in Atrial Fibrillation with a site in Spain are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies in Atrial Fibrillation with a site in Spain, or all of them as a file.
02

Study summary

Registry of all consecutive patients with atrial fibrillation from Heath Area of Vigo, since 2013 to 2020, in order to study therapy, mortality, cardiovascular complications and bleeding events.

Read the detailed description

Retrospective observational registry of patients diagnosed of atrial fibrillation between 2013 and 2020. Clinical, analytical and echocardiographic data will be recorded, as well as therapeutic prescription information. Data on mortality and cardioembolic and hemorrhagic events will be collected during follow-up. The aim is to study the prevalence and incidence of atrial fibrillation, the anticoagulant treatment according to cardioembolic risk, the thromboembolic events and hemorrhagic events, the risk of mortality (Cardiovascular, Non-Cardiovascular), the contemporary management (Rhythm control versus frequency control strategy), and other complications, such as heart failure, acute coronary syndrome or cancer.

03

Conditions studied

  • Atrial Fibrillation

Keywords

  • Atrial Fibrllation; Anticoagulation; Bleeding; Embolism.
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients with atrial fibrillation from Health Area of Vigo

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients with confirmed diagnoses of atrial fibrillation by .

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
15,000 participants (estimated)
Patient registry
No

Interventions

  • DrugAnticoagulation

    Study of prognostic impact according to oral anticoagulation therapy (Vitamin K Antagonists or Direct Oral Anticoagulants)

    Also known as: Vitamin K Antagonists or Direct Oral Anticoagulants

06

What researchers measure

Primary outcomes

  1. Mortality

    All cause Mortality

    Time frame: Follow-up (3 years)

Secondary outcomes

  1. Bleeding

    Bleeding according to International Society on Thrombosis and Haemostasis(ISTH) classiffication

    Time frame: Follow-up (3 years)

  2. Embolism

    Embolic events include ischemic stroke, transient ischemic attack (TIA), pulmonary embolism (PE), and systemic embolism (SE). Ischemic stroke was defined as sudden onset of a focal deficit consistent with occlusion of a major cerebral artery (documented by means of magnet resonance imaging \[MRI \]or computer tomography \[CT\]) and categorized. TIA was defined as a temporary neurologic deficit presumably due to reduced blood flow in a particular cerebral artery lasting for ≤24 hours with complete resolution of the neurologic deficit. A PE event was confirmed by spiral CT, perfusion-ventilation scan, pulmonary angiography, or autopsy) and resulted in a final PE diagnosis. A SE event was defined as any end-organ ischemia other than in the brain, heart, eyes, and lungs, caused by abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of another likely mechanism.

    Time frame: Follow-up (3 years)

07

Study locations

1 of 1 sites recruiting
  • Department of Cardiology, Hospital Álvaro Cunqueiro
    Vigo, Pontevedra 36312, Spain
    Recruiting
    • ANDRES IÑIGUEZ ROMO, MD, PhD · Contactandres.iniguez.romo@sergas.es
    • SERGIO RAPOSEIRAS ROUBIN, MD, PhD · Principal investigator
    • EMAD ABU ASSI, MD, PhD · Sub investigator
08

References and documents

Publications

  • Dominguez-Erquicia P, Raposeiras-Roubin S, Abu-Assi E, Bouzon-Iglesias P, Parada-Barcia JA, Lizancos-Castro A, Gonzalez-Garcia A, Noriega-Caro VA, Ledo-Pineiro A, Iglesias-Otero C, Gonzalez-Bermudez I, Iniguez-Romo A. Comparison of Outcomes in Patients With Atrial Fibrillation Under Oral Anticoagulation Therapy Analyzed by Body Weight (<60, 60 to 100, and >100 kg). Am J Cardiol. 2022 Dec 1;184:41-47. doi: 10.1016/j.amjcard.2022.07.028. Epub 2022 Sep 27. PubMed 36175253 ↗
  • Raposeiras-Roubin S, Abu-Assi E, Lizancos Castro A, Barreiro Pardal C, Melendo Viu M, Cespon Fernandez M, Blanco Prieto S, Rossello X, Ibanez B, Filgueiras-Rama D, Iniguez Romo A. Nutrition status, obesity and outcomes in patients with atrial fibrillation. Rev Esp Cardiol (Engl Ed). 2022 Oct;75(10):825-832. doi: 10.1016/j.rec.2022.01.006. Epub 2022 Mar 9. English, Spanish. PubMed 35279417 ↗
  • Cespon-Fernandez M, Raposeiras-Roubin S, Abu-Assi E, Melendo-Viu M, Garcia-Campo E, Iniguez-Romo A. Renin-Angiotensin System Inhibitors Prognostic Benefit in Older Patients with Atrial Fibrillation. J Am Med Dir Assoc. 2021 Oct;22(10):2190-2195. doi: 10.1016/j.jamda.2021.01.063. Epub 2021 Feb 16. PubMed 33607060 ↗

Individual participant data

Plan to share: Undecided — Data of CardioCHUVI-AF registry could be merge with other registries, always they have similar characteristics, with a same registry nature

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2018 (actual). Primary completion is estimated for Nov 2022, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2020
First posted
Apr 28, 2020
StartActual
Nov 26, 2018
Primary completionEst.
Nov 26, 2022
CompletionEst.
Nov 26, 2023
Last update
Apr 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04364516
Lead sponsor
Hospital Álvaro Cunqueiro
Responsible party
Sponsor
First posted
Apr 28, 2020
Start date
Nov 26, 2018
Primary completion
Nov 26, 2022 (estimated)
Completion
Nov 26, 2023 (estimated)
Last update
Apr 28, 2020

Study contacts

SONIA BLANCO PRIETO, PhD
Contact
raposeiras26@hotmail.com
620170387
EMAD ABU ASSI, PhD, MD
study director · University Hospital Alvaro Cunqueiro, Vigo, Spain
SERGIO RAPOSEIRAS ROUBIN, PhD, MD
principal investigator · University Hospital Alvaro Cunqueiro, Vigo, Spain
ANDRES IÑIGUEZ ROMO, PhD, MD
study chair · University Hospital Alvaro Cunqueiro, Vigo, Spain

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion